The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab
and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in …

As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence
and development, but as importantly, in their capacity to respond to treatment. While exciting …

Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …

Adoptive T‐cell therapy, where anti‐tumor T cells are first prepared in vitro, is attractive since
it facilitates the delivery of essential signals to selected subsets of anti‐tumor T cells without …

Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab
in Patients With Advanced Melanoma - PMC Back to Top Skip to main content NIH NLM Logo …

The adoptive transfer of T cells engineered with a chimeric antigen receptor (CAR)(hereafter
referred to as CAR-T cells) specific for the B lymphocyte antigen CD19 has shown …

Summary Background Previously, findings from CheckMate 238, a double-blind, phase 3
adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed …

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …

PURPOSE Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always
fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease …